-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, P5wUNs4OoSykVPBqi95SgOJ/HZaw77wG6pdUonLSjAt7IlfGgw9Dvs+C7guwjDNT HxMvq1gyOKZejs7glffJKA== 0000728889-04-000150.txt : 20040211 0000728889-04-000150.hdr.sgml : 20040211 20040211115449 ACCESSION NUMBER: 0000728889-04-000150 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-45385 FILM NUMBER: 04584680 BUSINESS ADDRESS: STREET 1: 150 INDUSTRIAL RD CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6506313100 MAIL ADDRESS: STREET 1: 150 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: OPPENHEIMER FUNDS INC CENTRAL INDEX KEY: 0000728889 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 6803 SOUTH TUCSON WAY STREET 2: N/A CITY: CENTENNIAL STATE: CO ZIP: 80112-3924 BUSINESS PHONE: 303-768-3200 MAIL ADDRESS: STREET 1: 6803 SOUTH TUCSON WAY STREET 2: N/A CITY: CENTENNIAL STATE: CO ZIP: 80112-3924 FORMER COMPANY: FORMER CONFORMED NAME: OPPENHEIMER MANAGEMENT CORP DATE OF NAME CHANGE: 19940131 SC 13G 1 nektartherapeutics.htm NEKTAR THERAPEUTICS Nektar Therapeutics
                                      UNITED STATES
                            SECURITIES AND EXCHANGE COMMISSION
                                  Washington, D.C. 20549


                                       SCHEDULE 13G
                        Under the Securities Exchange Act of 1934
                                    (Amendment No. 4)*

                                  Nektar Therapeutics

                                    (Name of Issuer)

                                      Common Stock

                             (Title of Class of Securities)

                                       640268108

                                     (CUSIP Number)
                                       12/31/2003

                (Date of Event Which Requires Filing of this Statement)



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[X]      Rule 13d-1(b)
[  ]     Rule 13d-1(c)
[  ]     Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial
filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in
a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be
"filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act (however, see the Notes).













 ------------------------------------------------------------------------------------------

  CUSIP No. 640268108

 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       1.       Names of Reporting Persons
                IRS Identification No:

                OppenheimerFunds, Inc.
                13-2527171
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       2.        Check the Appropriate Box if a Member of a Group (See Instructions):
                 Joint filing

 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       3.       SEC Use Only
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       4.       Citizenship or Place of Organization:
                Colorado
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------
   Number of
     Shares     5.    Sole Voting Power:
  Beneficially       0
    Owned by
      Each
   Reporting
  Person With
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

                6.    Shared Voting Power:
                     0
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

                7.    Sole Dispositive Power:
                     0
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

                8.    Shared Dispositive Power:
                     10,530,014*
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       9.       Aggregate Amount Beneficially Owned by Each Reporting Person:
                10,530,014* (beneficial ownership disclaimed pursuant to Rule 13d-4 of
                the Exchange Act of 1934)
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

      10.       Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
                Instructions)
                [  ]
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

      11.       Percent of Class Represented by Amount in Row (11):
                18.19%*
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

      12.       Type of Reporting Person (See Instructions):
                IA
 ------------------------------------------------------------------------------------------

*Position reflects the conversion of debentures to, and/or exercise of warrants for,
shares of common stock.







 ------------------------------------------------------------------------------------------

  CUSIP No. 640268108

 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       1.       Names of Reporting Persons:
                IRS Identification No:  93-1036175

                Oppenheimer Global Opportunities Fund (formerly Oppenheimer Global Growth
                & Income Fund)

 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       2.        Check the Appropriate Box if a Member of a Group (See Instructions):
                 Joint filing

 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       3.       SEC Use Only
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       4.       Citizenship or Place of Organization:
                Massachusetts
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------
   Number of
     Shares     5.      Sole Voting Power:
  Beneficially       8,000,000*
    Owned by
      Each
   Reporting
  Person With
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

                6.      Shared Voting Power:
                     0
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

                7.      Sole Dispositive Power:
                     0
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

                8.      Shared Dispositive Power:
                     8,000,000*
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

       9.       Aggregate Amount Beneficially Owned by Each Reporting Person:
                8,000,000*
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

      10.       Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
                Instructions)
                [  ]
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

      11.       Percent of Class Represented by Amount in Row (11):
                14.25%*
 ------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------

      12.       Type of Reporting Person (See Instructions):
                IV
 ------------------------------------------------------------------------------------------

*Position reflects the conversion of debentures to, and/or exercise of warrants for,
shares of common stock.





 ---------------------------------------------------------------------------------------
 Item:
 ---------------------------------------------------------------------------------------





 ---------------------------------------------------------------------------------------

      1(a)      Name of Issuer:
                Nektar Therapeutics
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      1(b)      Address of Issuer's Principal Executive Offices:
                150 Industrial Road
                San Carlos, CA   94070
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      2(a)      Name of Person Filing:
                (i)   OppenheimerFunds, Inc.
                (ii)  Oppenheimer Global Opportunities Fund (formerly Oppenheimer
                     Global Growth & Income Fund)
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      2(b)      Address of Principal Business Office or, if none, Residence:
                (i)  225 Liberty Street, 11th Floor
                     New York, NY 10281-1008
                (ii) 6803 S. Tucson Way
                     Centennial, CO  80112
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      2(c)      Citizenship:
                (i)   Colorado
                (ii)  Massachusetts
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      2(d)      Title of Class of Securities:
                Common Stock
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      2(e)      CUSIP Number:
                640268108
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

       3        If this statement is filed pursuant toss.240.13d-1(b) orss.240.13d-2(b)
                or (c), check whether the person filing is a:
                (i)    X    An investment adviser in accordance with
                      ----
              ss.240.13d-1(b)(1)(ii)(E)
                (ii)   X   Investment company registered under section 8 of the
                       ---
                Investment Company Act of     1940 (15 U.S. C. 80a-8).
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      4(a)      Amount beneficially owned:
                (i)   10,530,014 (beneficial ownership disclaimed pursuant to Rule
                    13d-4 of the Exchange Act of 1934)
                (ii)  8,000,000
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      4(b)      Percent of class:
                (i)   18.19% (reflects ownership reported in 4(b)(ii) below)
                (ii)  14.25%
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      4(c)      Number of shares as to which the person has:

          (i)   Sole power to vote or to direct the vote:
                (a)   0
                (b)   8,000,000
          (ii)  Shared power to vote or to direct the vote:
                (a)   0
                (b)   0
          (iii) Sole power to dispose or to direct the disposition of:
                (a)   0
                (b)   0
          (iv)  Shared power to dispose or to direct the disposition of:
                (a)   10,530,014
                (b)   8,000,000
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

       5.       Ownership of Five Percent or Less of a Class: [  ]
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

       6.       Ownership of More than Five Percent on Behalf of Another Person.:
                See Exhibit A hereto.
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

       7.       Identification and Classification of the Subsidiary Which Acquired the
                Security Being Reported on By the Parent Holding Company:
                N/A
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

       8.       Identification and Classification of Members of the Group:
                N/A
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

       9.       Notice of Dissolution of Group:
                N/A
 ---------------------------------------------------------------------------------------
 ---------------------------------------------------------------------------------------

      10.       Certification:
                By signing below I certify that, to the best of my knowledge and
                belief, the securities referred to above were acquired and are held in
                the ordinary course of business and were not acquired and are not held
                for the purpose of or with the effect of changing or influencing the
                control of the issuer of the securities and were not acquired and are
                not held in connection with or as a participant in any transaction
                having that purpose or effect.
 ---------------------------------------------------------------------------------------

                                        SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.


                                                            02/10/2004
                                                            Date

                                                             /s/ Frank J. Pavlak
                                                            Signature

                                                         Frank J. Pavlak, Vice President
                                                            Name/Title






                                        EXHIBIT A

      The respective Boards of Directors or Trustees of the registered investment
companies ("Funds") managed by OppenheimerFunds, Inc. ("OFI") that own shares of the
issuer can direct the disposition of dividends received by such Funds and can dispose of
such securities. Additionally, OFI shares the power to dispose of such securities with
the Board of Directors or Trustees of such Funds; however, the Boards of Directors or
Trustees of such Funds have delegated this responsibility to OFI as the Funds' investment
advisor under the respective investment advisory agreements. OFI has an interest relating
to five (5%) percent or more of such securities as disclosed on Page 2 hereof, by virtue
of the interest of five percent (5%) or more of such securities by Oppenheimer Global
Opportunities Fund (formerly Oppenheimer Global Growth and Income Fund) as disclosed on
pages 3 and 4 hereof.  OFI disclaims ownership of such securities, except as expressly
stated herein.




                                        EXHIBIT B

      The undersigned investment company hereby acknowledges and agrees that a report on
Schedule 13G filed by OppenheimerFunds, Inc. on or about the date hereof, relating to the
common stock of Nektar Therapeutics  is filed on behalf of the undersigned.

Dated:  February 10, 2004

                                                Oppenheimer Global Opportunities Fund
                                                (formerly Oppenheimer Global Growth and
                                                Income Fund)



                                                By:   /s/ Kathleen T. Ives

                                                      Kathleen T. Ives
                                                      Assistant Secretary





Nektar Therapeutic Systems a4 13g(123103).rtf

-----END PRIVACY-ENHANCED MESSAGE-----